December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

12.90 +0.46 (+3.74%)
Streaming Delayed Price Updated: 11:09 AM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
21 22 Next >
News headline image
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later ↗
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time. 
Via InvestorPlace
News headline image
3 Gene Editing Stocks With the Best Long-Term Potential ↗
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The growth-focused money manager is making moves. 
Via The Motley Fool
Expert Ratings for Intellia Therapeutics ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday saw 23 companies set new 52-week lows. 
Via Benzinga
The Latest Analyst Ratings for Intellia Therapeutics ↗
 
Via Benzinga
Analyst Ratings for Intellia Therapeutics ↗
 
Via Benzinga
News headline image
Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates ↗
 
Via Benzinga
News headline image
Recap: Intellia Therapeutics Q3 Earnings ↗
Intellia Therapeutics (NASDAQ:NTLA) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023 ↗
 
Via Benzinga
News headline image
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years ↗
Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow. 
Via The Motley Fool
News headline image
7 Analysts Have This to Say About Intellia Therapeutics ↗
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023 ↗
 
Via Benzinga
News headline image
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now) ↗
Both stocks have fallen brutally this year, but only one has a chance to recover soon. 
Via The Motley Fool
News headline image
3 Mid-Caps That Could Double in 2023
Mid-cap land has long been regarded as the ‘sweet spot’ for equity investors. Here are three mid-caps Wall Street sees as two-baggers over the next 12 months. 
Via MarketBeat
News headline image
7 ‘Next Big Things’ for Investors to Buy for 2023 ↗
The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown. 
Via InvestorPlace
News headline image
Ulta Beauty To Rally Around 22%? Here Are 10 Other Price Target Changes For Friday ↗
 
Via Benzinga
News headline image
NTLA Stock Falls as Intellia Therapeutics Announces Public Offering ↗
Intellia Therapeutics (NTLA) stock is falling hard on Thursday after the company announced a public stock offering of 6.6 million shares. 
Via InvestorPlace
News headline image
Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing ↗
Here's how Ark Invest's top holdings have performed in 2022. 
Via Investor's Business Daily
News headline image
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94% ↗
  Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday. 
Via Benzinga
News headline image
Earnings Preview For Intellia Therapeutics ↗
Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
News headline image
3 Cathie Wood Stocks to Buy and Hold for 10 Years ↗
The risks are formidable, but the chances of a massive gain are too much to pass up. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
The Top 5 Stocks Cathie Wood Is Buying This Week ↗
Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022 ↗
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago... 
Via Benzinga
News headline image
5 Top Stocks Cathie Wood Is Buying Right Now ↗
Cathie Wood's ARKK is down over 50% YTD, although the fund manager is still continuing her purchases of high conviction companies. 
Via InvestorPlace
News headline image
SVB Leerink Maintains Outperform Rating for Intellia Therapeutics: Here's What You Need To Know ↗
SVB Leerink has decided to maintain its Outperform rating of Intellia Therapeutics (NASDAQ:NTLA) and raise its price target from $152.00 to $158.00. Shares of Intellia Therapeutics are trading down... 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Intellia Therapeutics ↗
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.